Compare Amcor PLC (AMCR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amcor PLC vs Summit Therapeutics Inc — how do they compare? Amcor PLC trades at $43.01 (market cap $19.96B), while Summit Therapeutics Inc trades at $15.2 (market cap $11.84B). The key difference: Amcor PLC is the larger of the two by market cap, and Amcor PLC pays a 6.02% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AMCR | SMMT | |
|---|---|---|
Market Cap | $19.96B | $11.84B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $29.32 |
52-Week Low | $36.69 | $13.05 |
Enterprise Value | $35.08B | $11.26B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $43.18, up 1.12% today, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. Recent news highlights expansion in China and sustainable packaging partnerships, supporting growth prospects amid investor optimism.
The outlook for AMCR is positive, driven by earnings momentum and strategic initiatives, but risks include margin pressure and integration challenges from the Berry acquisition. With a consensus price target of $45.75, upside potential exists, though investors should monitor debt levels and competitive pressures in the packaging sector.
Summit Therapeutics (SMMT) trades at $15.25, down 1.49% today, with technical indicators showing bearish momentum despite recent positive clinical trial results for its lead oncology drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while cash flow trends show increasing operational cash burn. Analyst consensus remains bullish with 14 buy ratings and a $15.57 price target, reflecting optimism around the drug's potential despite financial challenges.
SMMT presents a high-risk, high-reward opportunity centered on binary clinical outcomes. Near-term catalysts include FDA review of ivonescimab, but substantial financial losses and dependence on a single asset create significant volatility. The stock's outlook hinges entirely on successful drug commercialization, with current valuations disconnected from fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
